Supplement encyclopedia

Bifidobacterium animalis

Bifidobacterium animalis is a species of bifidobacteria added to some probiotic products. The subspecies lactis is often used in studies. BB-12, HN019, UABla-12 and similar designations identify individual strains. These strains are available in capsules, powders and specially fortified dairy products.

Double-check the conclusions and review the sources before choosing a supplement.

Main conclusion

Potential benefits

  • BB-12 at 1 billion CFU daily may slightly increase the number of days with a stool in adults with infrequent stools and abdominal discomfort but no IBS: over four weeks, the difference from placebo was 0.39 days per week. No convincing advantage was found at 10 billion CFU.
  • In the same trial, neither dose of BB-12 provided convincing relief of abdominal discomfort compared with placebo.
  • In adults with functional constipation, HN019 showed no convincing advantage in the number of spontaneous bowel movements with a feeling of complete evacuation over eight weeks.
  • UABla-12 may slightly relieve abdominal pain in adults with irritable bowel syndrome. Over six weeks, the pain score on a 0–10 scale decreased by an average of 1.56 points versus 0.85 with placebo.
  • IDCC 4301 may slightly reduce fat mass in women with a BMI of 25–30. Over 12 weeks, it decreased by 0.45 kg with the supplement and 0.16 kg with placebo.
  • Fermented milk with GCL2505 may reduce the measured area of fat around the internal organs in Japanese adults with a BMI of 23–30. Over 12 weeks, the area on a CT image decreased by 5.1 cm², while it increased by 1.5 cm² with placebo.
  • In adults with overweight, B420 showed no convincing advantage in fat mass over six months. BLa80 showed no advantage in sleep-problem scores in young adults with sleep complaints over eight weeks.

[1] [2] [3] [4] [5] [6] [7]

What was studied

  • In children aged 3–12 taking antibiotics, adding BB-12 to yogurt showed no advantage over control yogurt in diarrhea frequency over 14 days.
  • Gas and temporary abdominal discomfort are possible. With severe illness or markedly weakened immunity, live probiotics are used after medical assessment because of infection risk.
  • With milk protein allergy, check the dairy product’s composition. For premature infants, probiotic use requires assessment by the treating doctor.

[1] [2] [3] [4]

Forms studied

  • BB-12 was studied in capsules providing 1 or 10 billion CFU daily for four weeks; HN019 as powder with water for eight weeks. CFU denotes the number of viable bacteria.
  • The fat-mass study used an IDCC 4301 capsule providing more than 5 billion CFU daily for 12 weeks; GCL2505 was studied in fermented milk at 100 g daily.
  • On the package, look for the full strain code, CFU count at the end of shelf life, and storage conditions.

[1] [2] [3] [4] [5]

How to get it from food

  • In the studied fermented-milk formulation, 100 g contained about 80 billion CFU of GCL2505 and 44 kcal. The product was refrigerated.
  • BB-12 has also been studied in yogurt and a yogurt smoothie. Check the package for the specific strain’s presence, count at the end of shelf life, and storage conditions.

[1] [2] [3] [4]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Days with a bowel movement — BB-12, 1 billion CFUThe number of days with a bowel movement per week increased by 1.54 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.39 days per week in favor of the supplement (p=0.0002).
2/4 LowConfidence is low. The finding concerns a small change in bowel movement frequency over four weeks. Eliminating all causes of infrequent bowel movements is outside its scope. This was an additional outcome in a large trial. The trial did not demonstrate an advantage on its prespecified primary response criterion.
1randomized trialEffect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. 343 received this dose and 453 received placebo.
  1. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗
Days with a bowel movement — BB-12, 10 billion CFUThe number of days with a bowel movement per week increased by 1.30 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.15 days per week, with no clear benefit at that time point (p=0.087).
2/4 LowConfidence is low. The finding concerns a small change in bowel movement frequency over four weeks. Eliminating all causes of infrequent bowel movements is outside its scope. The difference was more pronounced in weeks one and two. At week four, no clear advantage over placebo was observed. This was an additional outcome in the same trial.
1randomized trialEffect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. 452 received this dose and 453 received placebo.
  1. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗
More days with a bowel movement in at least two of four weeks — BB-12More days with a bowel movement than at baseline in at least two of the four weeks were reported by 82.9% of participants taking BB-12 and 78.7% taking placebo. There was no clear difference on this prespecified criterion (odds ratio 1.31, 95% CI 0.98–1.75).
3/4 ModerateConfidence is moderate. The trial was large, used a prespecified criterion and analyzed participants according to their original group assignments. The result does not establish that the effects were the same. The confidence interval allows for a small benefit. The two doses were pooled in this analysis.
1randomized trialEffect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. There were 1,248 participants, and the two BB-12 groups were pooled.
  1. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

How to read a probiotic dose
What is listedWhat it means
Strain and CFU countThe regimen depends on the specific strain, product and purpose. These studies do not establish a general daily requirement for B. animalis.
CFU at the end of shelf lifeThe number of live bacteria can decline during storage. Use the stated count at the end of shelf life and follow the recommended storage temperature.

Probiotics — Health Professional Fact Sheet (NIH ODS) ↗

Forms

Capsules: BB-12, UABla-12 and IDCC 4301 were studied in separate capsule products. Strains with different codes are not interchangeable. Check the live CFU count at the end of shelf life. Powders: HN019 was given in a sachet with water, B420 with a fruit smoothie and BLa80 with maltodextrin. Infants received CNCM I-3446 powder alongside a special formula and usual skin care. Dairy products: BB-12 yogurt and GCL2505 fermented milk have specific nutritional compositions. In the study, GCL2505 milk was kept refrigerated. Follow the storage instructions for the product you buy.

Guidance for each goal

Days with a bowel movement — BB-12, 1 billion CFU2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low. The finding concerns a small change in bowel movement frequency over four weeks. Eliminating all causes of infrequent bowel movements is outside its scope. This was an additional outcome in a large trial. The trial did not demonstrate an advantage on its prespecified primary response criterion.

The number of days with a bowel movement per week increased by 1.54 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.39 days per week in favor of the supplement (p=0.0002).

Study findings. The number of days with a bowel movement per week increased by 1.54 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.39 days per week in favor of the supplement (p=0.0002).

Studied regimenOne capsule with breakfast, 1 billion CFU/dayCapsules containing live B. animalis subsp. lactis BB-12 (DSM15954)
Duration and population4 weeksAdults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. 343 received this dose and 453 received placebo.

Comparator: Identical capsules without the probiotic

Days with a bowel movement — BB-12, 10 billion CFU2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low. The finding concerns a small change in bowel movement frequency over four weeks. Eliminating all causes of infrequent bowel movements is outside its scope. The difference was more pronounced in weeks one and two. At week four, no clear advantage over placebo was observed. This was an additional outcome in the same trial.

The number of days with a bowel movement per week increased by 1.30 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.15 days per week, with no clear benefit at that time point (p=0.087).

Study findings. The number of days with a bowel movement per week increased by 1.30 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.15 days per week, with no clear benefit at that time point (p=0.087).

Studied regimenOne capsule with breakfast, 10 billion CFU/dayCapsules containing live B. animalis subsp. lactis BB-12 (DSM15954)
Duration and population4 weeksAdults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. 452 received this dose and 453 received placebo.

Comparator: Identical capsules without the probiotic

More days with a bowel movement in at least two of four weeks — BB-123/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate. The trial was large, used a prespecified criterion and analyzed participants according to their original group assignments. The result does not establish that the effects were the same. The confidence interval allows for a small benefit. The two doses were pooled in this analysis.

More days with a bowel movement than at baseline in at least two of the four weeks were reported by 82.9% of participants taking BB-12 and 78.7% taking placebo. There was no clear difference on this prespecified criterion (odds ratio 1.31, 95% CI 0.98–1.75).

Study findings. More days with a bowel movement than at baseline in at least two of the four weeks were reported by 82.9% of participants taking BB-12 and 78.7% taking placebo. There was no clear difference on this prespecified criterion (odds ratio 1.31, 95% CI 0.98–1.75).

Studied regimenOne capsule with breakfast, 1 or 10 billion CFU/dayCapsules containing live B. animalis subsp. lactis BB-12 (DSM15954)
Duration and population4 weeksAdults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. There were 1,248 participants, and the two BB-12 groups were pooled.

Comparator: Identical capsules without the probiotic

Complete spontaneous bowel movements — HN0193/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate. The trial was well conducted, and 228 of 229 participants completed the treatment period. The changes shown are adjusted using a statistical model. The confidence interval allows for a small effect in either direction and does not establish an advantage for HN019 over placebo.

The weekly number of spontaneous bowel movements with a feeling of complete evacuation increased by 0.80 with HN019 and by 0.66 with placebo. The difference was 0.14 per week (95% CI −0.17 to 0.45, p=0.37). The trial did not demonstrate an advantage for the supplement.

Study findings. The weekly number of spontaneous bowel movements with a feeling of complete evacuation increased by 0.80 with HN019 and by 0.66 with placebo. The difference was 0.14 per week (95% CI −0.17 to 0.45, p=0.37). The trial did not demonstrate an advantage for the supplement.

Studied regimenOne sachet daily with room-temperature water at least 15 minutes before breakfast. The dose was 7 billion CFU at the start of the study and 4.69 billion by the end.Dried live HN019 in a 2 g sachet with maltodextrin and silicon dioxide
Duration and population8 weeks229 adults aged 18–70 years with functional constipation. 112 received HN019 and 117 received placebo. 85% were women.

Comparator: Identical powder without HN019

Relief of abdominal discomfort — BB-122/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low. Participants assessed how they felt by answering a weekly question, and relief was common with placebo as well. This outcome measures overall discomfort separately from the number of days with a bowel movement. The data for 13 participants were insufficient to determine whether they met this response criterion.

Relief in at least two of the four weeks was reported by 70.3% of participants taking 1 billion CFU, 67.1% taking 10 billion CFU and 68.1% taking placebo. Neither dose showed a clear benefit for overall abdominal discomfort.

Study findings. Relief in at least two of the four weeks was reported by 70.3% of participants taking 1 billion CFU, 67.1% taking 10 billion CFU and 68.1% taking placebo. Neither dose showed a clear benefit for overall abdominal discomfort.

Studied regimenOne capsule with breakfast, 1 or 10 billion CFU/dayCapsules containing live B. animalis subsp. lactis BB-12 (DSM15954)
Duration and population4 weeksAdults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. There were 1,248 participants across three groups.

Comparator: Identical capsules without the probiotic

Abdominal pain in IBS — UABla-122/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low. The finding comes from one study and applies specifically to pain in people with IBS. It does not extend to general discomfort in healthy people. Before group assignment, the study excluded people whose pain had already improved noticeably during a placebo run-in. This limits how well the result applies to typical consumers.

Abdominal pain decreased by 1.56 points with UABla-12 and by 0.85 with placebo on a 0–10 scale. The difference was 0.71 points in favor of the supplement (p=0.001).

Study findings. Abdominal pain decreased by 1.56 points with UABla-12 and by 0.85 with placebo on a 0–10 scale. The difference was 0.71 points in favor of the supplement (p=0.001).

Studied regimenOne capsule with water before a meal, at least 10 billion CFU/dayCapsule containing dried live B. animalis subsp. lactis UABla-12
Duration and population6 weeksAdults aged 18–70 years with irritable bowel syndrome (IBS) in India. Of 336 people assigned to groups, 330 were included in the analysis. 110 received UABla-12 and 109 received placebo.

Comparator: Capsule containing microcrystalline cellulose without the probiotic

Diarrhea during antibiotic treatment in children — BB-12 yogurt2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low. There were only five cases of diarrhea, so the estimated difference is imprecise. The trial compared two yogurts during prescribed antibiotic treatment. The result cannot be assumed to apply to every preparation, strain or age group.

Diarrhea occurred in 3 of 125 children in the BB-12 group and in 2 of 130 children in the group without BB-12 (p = 0.62). Diarrhea was defined as at least three loose stools per day for two consecutive days. The trial did not demonstrate an advantage from adding BB-12.

Study findings. Diarrhea occurred in 3 of 125 children in the BB-12 group and in 2 of 130 children in the group without BB-12 (p = 0.62). Diarrhea was defined as at least three loose stools per day for two consecutive days. The trial did not demonstrate an advantage from adding BB-12.

Studied regimenOne serving per day, about 10 billion CFU of BB-12. The article lists the serving size as 4 ounces.Yogurt containing live BB-12, Streptococcus thermophilus and Lactobacillus bulgaricus
Duration and populationYogurt for 14 days. The prescribed antibiotic course lasted 7 or 10 days.255 children aged 3–12 years with an acute respiratory tract infection who were prescribed an antibiotic. 125 received BB-12 and 130 were in the control group. Most received amoxicillin.

Comparator: Yogurt with the same standard starter cultures and no added BB-12

Fat mass — IDCC 43012/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low. The small difference was found in one study, mainly in middle-aged women. The analysis accounted for menopause, physical activity, diet and adherence. The reported final count of female participants contains an error. The group sizes shown here come from the results table.

Fat mass decreased by 0.45 kg with IDCC 4301 and by 0.16 kg with placebo, a 0.29 kg greater reduction with the supplement (p=0.0407). This measures a change in fat mass and does not imply an equal difference in total body weight.

Study findings. Fat mass decreased by 0.45 kg with IDCC 4301 and by 0.16 kg with placebo, a 0.29 kg greater reduction with the supplement (p=0.0407). This measures a change in fat mass and does not imply an equal difference in total body weight.

Studied regimenOne capsule daily, more than 5 billion CFUCapsule containing B. lactis IDCC 4301 (B. lactis Fit), with 500 mg of contents
Duration and population12 weeksWomen aged 20–65 years in South Korea with a BMI of 25–30. The article reports 99 participants. The results table lists 46 in the probiotic group and 47 in the placebo group.

Comparator: Identical capsule containing maltodextrin and dextrins, without the probiotic. Both groups maintained their usual diet and activity.

Visceral fat — GCL25052/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low. The result comes from one study of a specific dairy product. Of 160 participants, 137 were included in the analysis. Most exclusions were related to scan quality. The area on a single slice does not measure total fat volume or weight change.

Visceral fat area on a CT slice decreased by 5.1 cm² with GCL2505 and increased by 1.5 cm² with placebo. The difference was 6.6 cm² in favor of the study product. This measures area and does not indicate how many kilograms were lost.

Study findings. Visceral fat area on a CT slice decreased by 5.1 cm² with GCL2505 and increased by 1.5 cm² with placebo. The difference was 6.6 cm² in favor of the study product. This measures area and does not indicate how many kilograms were lost.

Studied regimen100 g daily, about 80 billion CFU per serving according to the methods sectionFermented milk containing live B. animalis subsp. lactis GCL2505
Duration and population12 weeks160 Japanese adults aged 20–65 years with a BMI of 23–30 were assigned to groups. The analysis included 137 participants, 69 receiving GCL2505 and 68 receiving placebo.

Comparator: Dairy product with the same nutritional composition and taste, without live starter cultures

Fat mass in the primary analysis — B4202/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low. Many participants did not meet all the treatment requirements, and earlier measurements were used for some missing values. Neither the positive results from additional analyses of participants who followed the protocol nor the data on the blend containing polydextrose supersede this finding for B420 alone.

In the primary analysis, B420 alone showed no clear difference from placebo in fat mass change (p=0.76). The analysis used the original group assignments and the last available measurements for participants who dropped out.

Study findings. In the primary analysis, B420 alone showed no clear difference from placebo in fat mass change (p=0.76). The analysis used the original group assignments and the last available measurements for participants who dropped out.

Studied regimen10 billion CFU/day, one sachet dailyB. animalis subsp. lactis B420 powder with 12 g of microcrystalline cellulose, mixed into 250 mL of fruit smoothie
Duration and population6 months225 adults aged 18–65 years with a BMI of 28–34.9 were assigned to four groups, and 209 were included in the overall analysis. The fat mass comparison used data from 47 people in the B420 group and 53 in the placebo group.

Comparator: 12 g of microcrystalline cellulose without B420 in the same smoothie

Severity of sleep problems — BLa801/4 Very lowRead moreCollapse
Confidence
1/4 Very lowConfidence is very low. The article text and captions disagree on participant counts and how the results are described. The figures shown here come from the allocation diagram and the ISI table. Sleep was assessed using participant responses. This questionnaire result does not establish that BLa80 prevents or treats insomnia.

After eight weeks, the Insomnia Severity Index (ISI) score was 2.6 points with BLa80 and 3.5 with placebo. There was no clear difference (p=0.211). A lower score indicates less severe sleep problems.

Study findings. After eight weeks, the Insomnia Severity Index (ISI) score was 2.6 points with BLa80 and 3.5 with placebo. There was no clear difference (p=0.211). A lower score indicates less severe sleep problems.

Studied regimen10 billion CFU/day0.1 g of BLa80 powder with 2.9 g of maltodextrin
Duration and population8 weeksAccording to the study flow diagram, 106 adults were assigned equally to the two groups. 52 in the BLa80 group and 49 in the placebo group completed the study. The average age was about 20 years, and participants reported sleep problems before treatment.

Comparator: 3 g of maltodextrin daily

Eczema severity in infants — CNCM I-34462/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low. This was one trial in infants with existing eczema. All groups received usual care and a special formula. This regimen is not intended for choosing a formula or dose for a child on your own. The result applies to eczema severity under the specified conditions.

Eczema severity on the SCORAD scale fell from 25.9 to 12.8 points with B. lactis and from 26.9 to 11.8 with placebo. The comparison across the three groups did not show an advantage for the supplement (p=0.7).

Study findings. Eczema severity on the SCORAD scale fell from 25.9 to 12.8 points with B. lactis and from 26.9 to 11.8 with placebo. The comparison across the three groups did not show an advantage for the supplement (p=0.7).

Studied regimen10 billion CFU/dayDried live B. lactis CNCM I-3446 in a powder sachet given with food, separately from the special infant formula
Duration and population12 weeks137 infants aged 3–6 months with eczema were assigned to three groups. 45 received B. lactis and 47 received placebo. All received usual topical care and an extensively hydrolyzed whey protein formula.

Comparator: Maltodextrin sachet without the probiotic, alongside the same formula and skin care

Safety and limitations

Healthy people may experience gas and temporary abdominal discomfort. In the BB-12 trial, product-related complaints included abdominal pain, nausea and loose stools. No severe product-related events were recorded. People with severe illness or significantly weakened immune systems should use live probiotics only after a medical assessment. Rare infections involving microorganisms entering the bloodstream have been reported. Do not choose probiotics for premature infants on your own. The FDA warns of a risk of serious and sometimes fatal infections. The fatal case described in the warning was linked to B. longum rather than B. animalis. The pediatric studies describe specific products and monitoring by physicians. They do not establish a general dose for infants or for use during pregnancy or breastfeeding. Check the ingredients of any dairy product intended for someone with a milk protein allergy.

Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗ · Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years ↗ · Probiotics — Health Professional Fact Sheet (NIH ODS) ↗ · Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA) ↗ · Probiotics for treating eczema ↗

Interactions

WithEffectActionSource
AntibioticsAntibiotics can reduce the effect of some live probiotics. This is a general interaction, and the effect depends on the antibiotic and the strain.If you have been prescribed an antibiotic, ask your doctor or pharmacist which probiotic product to use and how to take it. These studies do not establish a single dosing interval that applies to all strains.Dietary Supplements for Immune Function and Infectious Diseases — NIH ODS ↗

Food sources

The table shows the GCL2505 fermented milk formulation used in the study. Other food options with added BB-12 are yogurt and a yogurt smoothie. One yogurt drink retained at least 10 billion CFU per 100 mL at the end of shelf life when stored at 4 °C. The smoothie serving was 240 g, and the live bacteria count changed during storage. For a product you buy, check the specific strain, the count at the end of shelf life and the storage conditions.

Food composition

FoodGroupAmountServingCaloriesSources
GCL2505 fermented milkRefrigerated product used in the studyFermented dairy products80 billion CFU / 100 g100 g serving, about 80 billion CFU. The study formulation was kept refrigerated.100 g · 80 billion CFU · 44 kcal44 kcal / 100 gEffect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial ↗

Effect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗Days with a bowel movement — BB-12, 1 billion CFU | Days with a bowel movement — BB-12, 10 billion CFU | More days with a bowel movement in at least two of four weeks — BB-12 | Relief of abdominal discomfort — BB-12Days with a bowel movement — BB-12, 1 billion CFU: Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. 343 received this dose and 453 received placebo. Days with a bowel movement — BB-12, 10 billion CFU: Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. 452 received this dose and 453 received placebo. More days with a bowel movement in at least two of four weeks — BB-12: Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. There were 1,248 participants, and the two BB-12 groups were pooled. Relief of abdominal discomfort — BB-12: Adults aged 18–70 years with 2–4 days with a bowel movement per week and abdominal discomfort, without irritable bowel syndrome. There were 1,248 participants across three groups.Days with a bowel movement — BB-12, 1 billion CFU: Capsules containing live B. animalis subsp. lactis BB-12 (DSM15954). One capsule with breakfast, 1 billion CFU/day for 4 weeks. Comparator: Identical capsules without the probiotic. Days with a bowel movement — BB-12, 10 billion CFU: Capsules containing live B. animalis subsp. lactis BB-12 (DSM15954). One capsule with breakfast, 10 billion CFU/day for 4 weeks. Comparator: Identical capsules without the probiotic. More days with a bowel movement in at least two of four weeks — BB-12: Capsules containing live B. animalis subsp. lactis BB-12 (DSM15954). One capsule with breakfast, 1 or 10 billion CFU/day for 4 weeks. Comparator: Identical capsules without the probiotic. Relief of abdominal discomfort — BB-12: Capsules containing live B. animalis subsp. lactis BB-12 (DSM15954). One capsule with breakfast, 1 or 10 billion CFU/day for 4 weeks. Comparator: Identical capsules without the probiotic.Days with a bowel movement — BB-12, 1 billion CFU: The number of days with a bowel movement per week increased by 1.54 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.39 days per week in favor of the supplement (p=0.0002). Days with a bowel movement — BB-12, 10 billion CFU: The number of days with a bowel movement per week increased by 1.30 with BB-12 and by 1.15 with placebo. By week four, the difference was 0.15 days per week, with no clear benefit at that time point (p=0.087). More days with a bowel movement in at least two of four weeks — BB-12: More days with a bowel movement than at baseline in at least two of the four weeks were reported by 82.9% of participants taking BB-12 and 78.7% taking placebo. There was no clear difference on this prespecified criterion (odds ratio 1.31, 95% CI 0.98–1.75). Relief of abdominal discomfort — BB-12: Relief in at least two of the four weeks was reported by 70.3% of participants taking 1 billion CFU, 67.1% taking 10 billion CFU and 68.1% taking placebo. Neither dose showed a clear benefit for overall abdominal discomfort.
Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial ↗Complete spontaneous bowel movements — HN019229 adults aged 18–70 years with functional constipation. 112 received HN019 and 117 received placebo. 85% were women.Dried live HN019 in a 2 g sachet with maltodextrin and silicon dioxide. One sachet daily with room-temperature water at least 15 minutes before breakfast for 8 weeks. The dose was 7 billion CFU at the start of the study and 4.69 billion by the end. Comparator: Identical powder without HN019.The weekly number of spontaneous bowel movements with a feeling of complete evacuation increased by 0.80 with HN019 and by 0.66 with placebo. The difference was 0.14 per week (95% CI −0.17 to 0.45, p=0.37). The trial did not demonstrate an advantage for the supplement.

Sources

Sources
  1. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial ↗
  2. Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial ↗
  3. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial ↗
  4. Probiotic intervention not beneficial to prevent antibiotic-associated diarrhea in absence of antibiotic-induced microbiome disruption ↗
  5. Bifidobacterium lactis IDCC 4301 (B. lactis Fit™) supplementation effects on body fat, serum triglyceride, and adipokine ratio in obese women: a randomized clinical trial ↗
  6. Effect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial ↗
  7. Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial ↗
  8. A double blinded randomized placebo trial of Bifidobacterium animalis subsp. lactis BLa80 on sleep quality and gut microbiota in healthy adults ↗
  9. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years ↗
  10. Probiotics — Health Professional Fact Sheet (NIH ODS) ↗
  11. Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA) ↗
  12. Safety of Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12-supplemented yogurt in healthy adults on antibiotics: a phase I safety study ↗
  13. Consumption of Bifidobacterium animalis subsp. lactis BB-12 impacts upper respiratory tract infection and the function of NK and T cells in healthy adults ↗
  14. Probiotics for treating eczema ↗
  15. Dietary Supplements for Immune Function and Infectious Diseases — NIH ODS ↗
  16. Matrix Effects on the Delivery Efficacy of Bifidobacterium animalis subsp. lactis BB-12 on Fecal Microbiota, Gut Transit Time, and Short-Chain Fatty Acids in Healthy Young Adults ↗